Jim Simons
CTKB icon

Jim Simons’s Cytek Biosciences CTKB Stock Holding History

Jim Simons’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.96M Buy
676,700
+1,700
+0.3% +$8.03K ﹤0.01% 1670
2025
Q4 		$3.41M Sell
675,000
-120,544
-15% -$560K 0.01% 1560
2025
Q3 		$2.76M Sell
795,544
-267,595
-25% -$1M ﹤0.01% 1863
2025
Q2 		$3.61M Buy
1,063,139
+375,539
+55% +$1.25M ﹤0.01% 1728
2025
Q1 		$2.76M Buy
687,600
+225,000
+49% +$1.17M ﹤0.01% 1795
2024
Q4 		$3M Buy
462,600
+251,000
+119% +$1.5M ﹤0.01% 1772
2024
Q3 		$1.17M Sell
211,600
-22,300
-10% -$126K ﹤0.01% 2344
2024
Q2 		$1.31M Buy
+233,900
New +$1.4M ﹤0.01% 2164
2023
Q4 		– Sell
-296,900
Closed -$1.64M – 3797
2023
Q3 		$1.64M Buy
+296,900
New +$2.38M ﹤0.01% 1978
2023
Q2 		– Sell
-353,500
Closed -$3.25M – 3980
2023
Q1 		$3.25M Sell
353,500
-38,300
-10% -$412K ﹤0.01% 1730
2022
Q4 		$4M Buy
391,800
+179,900
+85% +$2.42M 0.01% 1651
2022
Q3 		$3.12M Buy
211,900
+49,000
+30% +$636K ﹤0.01% 1736
2022
Q2 		$1.75M Buy
162,900
+108,600
+200% +$1.08M ﹤0.01% 2291
2022
Q1 		$585K Sell
54,300
-54,700
-50% -$739K ﹤0.01% 3092
2021
Q4 		$1.78M Buy
+109,000
New +$2.28M ﹤0.01% 2237

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jim Simons's CTKB Position: Q1 2026 in Review

Jim Simons increased its Cytek Biosciences (CTKB) stake by 0.25% in Q1 2026, buying an estimated $8.03K and bringing the position to 676,700 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1670.

Jim Simons first reported a position in CTKB in Q4 2021 and has held it in 15 quarters since. The position peaked at $4M in Q4 2022. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Jim Simons held 676,700 shares of Cytek Biosciences worth $2.96M as of Q1 2026.
  • Jim Simons bought 1,700 Cytek Biosciences shares in Q1 2026, an estimated $8.03K.
  • Cytek Biosciences made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1670 holding.
  • Jim Simons first reported a position in Cytek Biosciences in Q4 2021 and has held it in 15 quarters since.
  • Jim Simons's Cytek Biosciences position peaked at $4M in Q4 2022.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.